GPCR Biologics Drug Discovery Services
Drugs of the biological compounds class are made by living cells. Several special qualities of biologics are not achievable with small-molecule medications. Numerous biologics benefit from the characteristics of antibodies; specifically, the Fc region can be modified to lengthen the half-life of the medicine and cause cytotoxicity in cells that are dependent on the antibody. The ability to merge antibodies to form bispecific molecules that target two separate receptors or biparatopic molecules that target two epitopes on the same receptor is another benefit of biologics. GPCR biologics, which may create peptides, antibodies, and antibody fragments with desired drug-like qualities, is a service that Creative Biolabs provides. Our services include:
GPCR Biologics Drug Discovery Services in Creative Biolabs
- AI-based GPCR Biologics Drug Discovery Services
New approaches in artificial intelligence (AI) have the potential to completely change drug development, from preliminary research to pre-clinical and clinical phases. By utilizing large-scale biomedical data, AI-based models have proven to be quicker and more efficient than conventional biological experiments. Excellent chances exist to uncover therapeutic candidates for prospective genetic/multi-omics-evidenced pharmacological targets in human diseases thanks to AI's superior algorithms. Artificial Intelligence has improved our ability to assess and reduce immunogenicity. Artificial intelligence models that have been trained on large datasets of naturally occurring antibody sequences from different species are able to identify minute variations that conventional sequence-identity-based techniques could miss.
- GPCR SdAb Development Services
At the moment, research is concentrated on antibodies and fragments that target GPCRs. The ability to target cryptic epitopes due to fragments' small size is one of their key advantages. Fab fragments and single-chain variable fragments (scFvs), which are smaller than typical Abs, are two popular mAb-derived fragments. However, in comparison to their full-length counterparts, these Ab fragments are more likely to cluster and often exhibit lower affinity for their target. The unique class of Ab fragments known as single domain Ab fragments (sdAbs) is formed from heavy chain-only Abs that are only seen in cartilaginous fishes or camelids. We refer to these sdAbs as VHHs. These Ab fragments have relatively high stability, solubility, and affinity for their target because their CDR regions were improved during in vivo selection and maturation in these animals, as they are generated from naturally occurring antibodies that lack light chains. These characteristics, along with their comparatively tiny size of 13–15 kDa, allow them to target non-linear epitopes and short extracellular domains on GPCRs.
Fig.1 The applications of GPCR antibodies and antibody fragments.1
The use of antibodies and related biologics to target GPCRs offers a special chance for medication development. Though just about 100 GPCRs are the target of a third of FDA-approved medications, GPCRs are essential to many physiological functions. GPCR de-organization, GPCR signaling regulation, GPCR interaction disruption, and targeting of disease cells overexpressing GPCRs are all made possible by biologics. New approaches to the therapy of numerous diseases will be made possible by the development of GPCR biologics for therapeutic use. Please contact us for more information about our GPCR biologics drug discovery services.
Reference
- De Groof, Timo WM, et al. "Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs." Molecular and cellular endocrinology 484 (2019): 15-24.
